Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: A meta-analysis of individual data from 6171 patients

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2604-2609

  Cassidy, J ^a   Saltz, L ^b   Twelves, C ^c   Van cutsem, E ^d   Hoff, P ^e   Kang, Y ^f   Saini, J P ^g   Gilberg, F ^g   Cunningham, D ^h  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HOSPITAL SÍRIO LIBANÊS   (Brazil)

^f Asan Medical Center   (South Korea)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Capecitabine; Colorectal cancer; Gastric cancer; Meta analysis; Overall survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; COLORECTAL CANCER; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; MONOTHERAPY; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 80052529758     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr031     Document Type: Article

References (17)

1. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
2. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
3. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
4. Cassidy J, Clarke S, Diaz Rubio E et al. A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
5. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19: 1720-1726.
6. Saltz L, Clarke S, Diaz-Rubio E et al. Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
7. Kang YK, Kang WK, Shin DB et al. Capecitabine-cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol 2009; 20: 666-673.
8. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25: 4569-4574.
9. Graf W, Pahlman L, Bergstrom R et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-563.
10. Massacesi C, Norman A, Price T et al. A clinical nomogram for predicting longterm survival in advanced colorectal cancer. Eur J Cancer 2000; 36: 2044-2052.
11. Tang PA, Bentzen SM, Chen EX et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25: 4562-4568.
12. Louvet C, de Gramont A, Tournigand C et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91: 2033-2038.
13. Buyse M, Burzykowski T, Michiels S et al. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008; 17: 467-475.
14. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
15. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534.
16. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX vs. FOLFOX4: update of efficacy results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC). Presented at the ASCO GI Cancers Symposium, 25-27 January, 2008 (Abstr 341).
17. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-5917.